Vanda Pharmaceuticals Inc.
$6.99
▼
-0.99%
2026-04-21 10:09:00
www.vandapharma.com
NGM: VNDA
Explore Vanda Pharmaceuticals Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$417.3 M
Current Price
$6.99
52W High / Low
$9.94 / $3.81
Stock P/E
—
Book Value
$5.54
Dividend Yield
—
ROCE
-43.97%
ROE
-50.93%
Face Value
—
EPS
$-3.74
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
533
Beta
0.71
Debt / Equity
3.86
Current Ratio
2.39
Quick Ratio
2.38
Forward P/E
36.1
Price / Sales
1.97
Enterprise Value
$175.53 M
EV / EBITDA
-1.23
EV / Revenue
0.81
Rating
Strong Buy
Target Price
$15.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Abeona Therapeutics Inc. | $5.48 | 4.39 | $312.63 M | — | -47.08% | 70.05% | $7.54 / $4 | $2.89 |
| 2. | Veradermics, Incorporated | $73.97 | — | $2.85 B | — | -49.88% | -72.06% | $80.9 / $32 | $-131.48 |
| 3. | MediciNova, Inc. | $1.47 | — | $71.37 M | — | -31.77% | -25.5% | $1.96 / $1.17 | $0.84 |
| 4. | MetaVia Inc. | $1.51 | — | $7.13 M | — | -250.37% | -1.96% | $19.03 / $1.17 | $2.31 |
| 5. | Nuvalent, Inc. | $107.99 | — | $8.48 B | — | -31.35% | -36.7% | $113.02 / $63.55 | $15.96 |
| 6. | GridAI Technologies Corp. | $2.79 | — | $9.38 M | — | -27% | -58.82% | $5.84 / $0.97 | — |
| 7. | Larimar Therapeutics, Inc. | $4.81 | — | $499.68 M | — | -212.84% | -1.33% | $6.42 / $1.73 | $0.94 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 57.22 M | 56.26 M | 52.59 M | 50.04 M | 53.19 M |
| Operating Profit | -40.35 M | -31.28 M | -38.5 M | -41.03 M | -10.28 M |
| Net Profit | -141.19 M | -22.59 M | -27.21 M | -29.49 M | -4.91 M |
| EPS in Rs | -2.39 | -0.38 | -0.46 | -0.5 | -0.08 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 216.1 M | 198.77 M | 192.64 M | 254.38 M |
| Operating Profit | -151.17 M | -40.66 M | -13.95 M | 6.33 M |
| Net Profit | -220.47 M | -18.9 M | 2.51 M | 6.28 M |
| EPS in Rs | -3.73 | -0.32 | 0.04 | 0.11 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 488.95 M | 656.2 M | 648.44 M | 634.25 M |
| Total Liabilities | 161.76 M | 117.66 M | 103.53 M | 107.05 M |
| Equity | 327.19 M | 538.55 M | 544.91 M | 527.2 M |
| Current Assets | 347.26 M | 438.89 M | 432.95 M | 519.29 M |
| Current Liabilities | 145.16 M | 99.98 M | 87.7 M | 91.44 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -109.44 M | -15.76 M | 12.8 M | 31.98 M |
| Investing CF | 94.86 M | -17.43 M | -12.06 M | 49.92 M |
| Financing CF | -2.91 M | -0.15 M | 0 M | 0.73 M |
| Free CF | -110.44 M | -16.25 M | 12.42 M | 31.3 M |
| Capex | -1 M | -0.49 M | -0.38 M | -0.68 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 8.72% | 3.18% | -24.27% | — |
| Earnings Growth % | -1066.53% | -853.29% | -60.02% | — |
| Profit Margin % | -102.02% | -9.51% | 1.3% | 2.47% |
| Operating Margin % | -69.95% | -20.46% | -7.24% | 2.49% |
| Gross Margin % | 93.96% | 94.31% | 92.32% | 90.45% |
| EBITDA Margin % | -64.44% | -15.53% | -4.99% | 3.56% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.